Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
7–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients with a diagnosis of asthma according to the American Thoracic Society Criteria
Patients aged 7 to 12 years inclusive
Patients able to perform spirometry
Patients with FEV1 (forced expiratory volume in the first second) ≥ 80% of predicted normal value after saline
Patients with PD20 (provocative dose that reduces FEV1 by 20 %) metacholine lower than 8 mg/ml
Patients or responsible relatives willing and able to sign an informed consent form
You may not be if
Patients on treatment for or suspected as having glaucoma
Patients with known allergy of contra-indications to either salbutamol, ipratropium or their excipients
Patients suspected on clinical grounds to have pneumonia, pneumothorax or pneumomediastinum
Patients with a history of chest surgery
Patients with other respiratory conditions if diagnosed. These include pulmonary fibrosis, bronchiectasis, cystic fibrosis, sarcoidosis, pulmonary tuberculosis, pulmonary complications of AIDS
Patients requiring drugs for the treatment of the acute asthma attack other than the study drugs or oxygen
Patients who have been previously recruited into this study
Patients with myocardiopathy, pulmonary edema or other life threatening diseases, which in the judgement of the pediatrician precludes their entry into the study
Patients with obvious or previously diagnosed serious hepatic or renal disease
Patients who have been under the following drugs within the specified periods of time prior to determination of Baseline FEV1 or metacholine challenge
* INHALED:
* Short acting β2 agonists: 6 hours
* Long acting β2 agonists: 12 hours
* Ipratropium bromide: 8 hours
* DSCG (disodium cromoglicate): 7 days
* Nedocromil: 7 days
* ORAL:
* Short acting β2 agonists: 18 hours
* Anticholinergics: 7 days
* Short acting theophylline: 24 hours
* Long acting theophylline: 72 hours
* Antihistamines: 7 days
* Astemizole: 3 months
* Ketotifen: 3 months
* INHALED or ORAL: Other investigational drugs: 3 months
